{"id":70,"date":"2025-05-06T17:37:38","date_gmt":"2025-05-06T17:37:38","guid":{"rendered":"https:\/\/gyneoncologyca.freestyledev.co.uk\/?page_id=70"},"modified":"2026-02-23T17:08:29","modified_gmt":"2026-02-23T17:08:29","slug":"members-resources","status":"publish","type":"page","link":"https:\/\/gyneoncologyca.freestyledev.co.uk\/fr\/members-resources\/","title":{"rendered":"Members Resources"},"content":{"rendered":"

[et_pb_section fb_built=”1″ module_id=”guidelines” _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Guidelines” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

The GOC Guidelines are statements that provide recommendations for the diagnosis, treatment, or prevention of gynecologic cancers based on the best available evidence and expert consensus.<\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.27.5″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Guidelines – A work in progress” url=”https:\/\/gyneoncologyca.freestyledev.co.uk\/wp-content\/uploads\/2026\/01\/GOC-Guidelines-In-Progress.pdf” url_new_window=”on” use_icon=”on” font_icon=”h||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.5″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight||on|||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

<\/span>The Gynecologic Oncology of Canada (GOC) is currently developing and
updating clinical guidelines to address key areas of practice in gynecologic oncology.<\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Lignes directrices canadiennes sur la colposcopie” url=”https:\/\/online.flippingbook.com\/view\/854352226\/” url_new_window=”on” use_icon=”on” font_icon=”h||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.4″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight||on|||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

<\/span>Une approche de la prise en charge et de la surveillance de la dysplasie du col de l\u2019ut\u00e9rus fond\u00e9e sur le risque, 2023<\/span><\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Lignes directrices canadiennes sur la colposcopie” url=”https:\/\/online.flippingbook.com\/view\/854352226\/” url_new_window=”on” use_icon=”on” font_icon=”h||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.4″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight||on|||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

<\/span>Une approche de la prise en charge et de la surveillance de la dysplasie du col de l\u2019ut\u00e9rus fond\u00e9e sur le risque, 2023<\/span><\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Current Oncology | Free Full-Text” url=”https:\/\/online.flippingbook.com\/view\/789069227\/” url_new_window=”on” use_icon=”on” font_icon=”h||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.4″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight||on|||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

<\/span>Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations (mdpi.com)<\/p>\n

[\/et_pb_blurb][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.27.5″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Lignes directrices canadiennes” url=”https:\/\/online.flippingbook.com\/view\/853923599\/” url_new_window=”on” use_icon=”on” font_icon=”h||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.4″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight||on|||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

<\/span>Sur la prise en charge des personnes ayant obtenu un r\u00e9sultat positif au test de d\u00e9tection des virus du papillome humain et orientations pour certaines populations<\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Current Oncology | PDF Download” url=”https:\/\/gyneoncologyca.freestyledev.co.uk\/wp-content\/uploads\/2025\/10\/curroncol-32-00594-1-1.pdf” url_new_window=”on” use_icon=”on” font_icon=”h||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.4″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight||on|||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

<\/span>HPV Testing, Self-Collection, and Vaccination: A Comprehensive Approach to Cervical Cancer Prevention<\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.27.5″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”GI\/Hepatic – irAEs” url=”https:\/\/gyneoncologyca.freestyledev.co.uk\/wp-content\/uploads\/2026\/02\/Hepatitis_GI_irAEs_one-pager.pdf” url_new_window=”on” use_icon=”on” font_icon=”||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.5″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight|||||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

Key principles of hepatic and GI immune-related adverse events<\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Rheumatologic Immune – irAEs” url=”https:\/\/gyneoncologyca.freestyledev.co.uk\/wp-content\/uploads\/2026\/02\/Rheumatologic_irAEs_one-pager.pdf” url_new_window=”on” use_icon=”on” font_icon=”||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.5″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight|||||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

Key principles of rheumatologic immune-related adverse events (irAEs)<\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Endocrine – irAEs” url=”https:\/\/gyneoncologyca.freestyledev.co.uk\/wp-content\/uploads\/2026\/02\/Endocrine_irAEs_one-pager.pdf” url_new_window=”on” use_icon=”on” font_icon=”||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.5″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight|||||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

Principles of endocrine immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICIs)<\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Dermatology – irAEs” url=”https:\/\/gyneoncologyca.freestyledev.co.uk\/wp-content\/uploads\/2026\/02\/Derm-irAEs-Highlights_one-pager.pdf” url_new_window=”on” use_icon=”on” font_icon=”||divi||400″ icon_color=”#0774BA” icon_placement=”left” _builder_version=”4.27.5″ _module_preset=”default” header_font=”–et_global_body_font|–et_global_body_font_weight|||||||” header_text_color=”#0774BA” header_font_size=”16px” header_line_height=”1.6em” global_colors_info=”{}”]<\/p>\n

Managing Skin Toxicities Related to Immune Checkpoint Inhibitor Therapy<\/p>\n

[\/et_pb_blurb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _dynamic_attributes=”link_option_url” _module_preset=”default” background_enable_color=”off” use_background_color_gradient=”on” background_color_gradient_direction=”125deg” background_color_gradient_stops=”rgba(0,52,84,0.9) 40%|rgba(7,116,186,0.65) 40%” background_color_gradient_overlays_image=”on” background_image=”https:\/\/gyneoncologyca.freestyledev.co.uk\/wp-content\/uploads\/2025\/05\/homepage-full-screen.jpg” link_option_url=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjE2MSJ9fQ==@” global_module=”625″ locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Upcoming Events” _builder_version=”4.27.4″ _module_preset=”default” title_text_color=”#FFFFFF” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” header_3_text_color=”#FFFFFF” width=”50%” custom_css_main_element=”display:inline-block;” locked=”off” global_colors_info=”{}”]<\/p>\n

2026<\/h3>\n